MAPK8 and melanoma: We thus tested cell viabilities by using the combinatorial drug regimens of cilengitide + linsitinib and cilengitide + JNK-IN-8 across multiple cancer cell lines, including melanoma (MeWo), head and neck squamous carcinoma (FaDu), and breast cancer (MCF7) cells.